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  Subchondral bone remodelling is an integral part of osteo-
arthritis and involves the development of subchondral 
sclerosis seen on plain imaging, along with osteophyte 
formation.
  The development of these changes is due to persistent 
abnormal mechanical stresses which create a cellular and 
biomolecular response to microfractures in the subchon-
dral bone and osteochondral junction.
  An early sign is bone marrow lesions seen on MRI scan-
ning. Healing can occur at this stage by correcting the 
abnormal loads. Persistence leads to what is thought to be 
a delayed union or nonunion response by the bone.
  Microfractures of the osteochondral junction, coupled 
with articular cartilage fissuring and loss, allows synovial 
fluid to penetrate the subchondral bone along with cyto-
kines and other molecules reacting with the bone cells to 
increase the pathological effects.
  This review gives an overview of the current thoughts on 
subchondral bone remodelling in osteoarthritis that is 
aimed at orthopaedic surgeons to help in the understand-
ing of the pathogenesis of osteoarthritis and the role of 
surgical management.
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Introduction
Subchondral bone is the bedrock of a joint on which sits 
the articular cartilage. Traditionally, osteoarthritis (OA) 
has been considered to be wear and tear of articular carti-
lage, but more recent evidence has shown that subchon-
dral bone disturbance and synovial inflammation can 
initiate and lead to disease progression.1 OA is character-
ised as ‘a multi-disease with inflammation, immune and 
central nervous system dysfunction playing central roles 
in whole joint damage, injury progression, pain and disa-
bility’.2 It is distinguished from rheumatoid arthritis by the 
hypertrophic changes in the subchondral bone seen on 
plain radiographs. The pathognomonic signs of OA on 
plain radiographs are joint space narrowing, osteophytes, 
subchondral sclerosis and subchondral cysts. The sub-
chondral sclerosis is due to the thickening of the subchon-
dral bone. The osteochondral junction is the transition 
between soft and hard tissues and so is critical in absorb-
ing the stresses during joint loading. Abnormal loading 
leads to microfractures within the osteochondral junction 
and within the subchondral bone. The advent of MRI 
scanning has shown bone marrow lesions within the sub-
chondral bone, associated with degenerative changes in 
the joint. The subchondral signals are now termed ‘bone 
marrow lesions’ (previously bone marrow oedema) and 
do not just reflect increased vascularity. The histological 
features change over the course of OA progression; 
increased vascularity occurs early. Increased radiological 
bone density (sclerosis) is thought to be a later finding 
when changes have become permanent and drug thera-
pies aimed at reversing the disorder are not possible.3 
Besides the altered vascularity, the bone marrow lesions 
also show subchondral microdamage.4 With increased 
subchondral sclerosis, there is a reduction in the flexibility 
of the osteochondral junction and a reduction in the den-
sity of the underlying subchondral bone.5
Articular cartilage degeneration itself comes from a 
number of different molecular pathways6 that include 
matrix metalloproteinases (MMP-1, MMP-13),7 comple-
ment component-5,8 hypoxia-inducible factor 2α (HIF-
2α)9,10 and inhibition of TGF-β signalling.11 ‘Studies aimed 
at elucidating the pathophysiological roles of these enzymes 
in cartilage will contribute to our understanding of OA 
pathogenesis and enable design of targeted inhibitors that 
effectively target metalloproteinase-mediated cartilage 
degradation while sparing cartilage repair pathways’.12 
These enzymes are produced by the cells of the tissues that 
make up the joint, in particular the synovial membrane. As 
OA progresses, the abnormal signals from one cell can lead 
to responses from other cell types and drive the pathologi-
cal process. The osteochondral junction (‘tidemark’) is nor-
mally a barrier to this type of ‘cross-talk’. Loss of its integrity 
therefore is critical in the progression of OA.
This review explores our current understanding of sub-
chondral bone in OA. It cannot be treated in isolation as all 
tissues that make up a joint are altered and interplay in the 
process. It should also be remembered that OA in humans 
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is a clinical diagnosis and much of the biochemical path-
ways, especially early in the disorder, come from animal 
studies and may not translate into humans. The pathogno-
monic feature of OA in humans is pain. This cannot be seen 
on imaging and is not reflected in biochemical pathways.
The normal osteochondral junction
Anatomy of the osteochondral junction
The osteochondral junction is the tissue layer between the 
deep layers of the articular cartilage and the underlying sub-
chondral bone (Fig. 1). It comprises the non-calcified deeper 
articular cartilage, the tidemark, the calcified layer, the 
cement line and the subchondral bone plate.5 On histologi-
cal sections, the layer between the deep articular cartilage 
and the calcified layer appears as a basophilic line and is 
called the ‘tidemark’. The cement line is the junction 
between bone and the calcified zone of the cartilage. The 
epiphyseal bone contains sensory nerves and blood vessels. 
In the normal adult, the osteochondral junction seals these 
off from the deep layer of articular cartilage. The absence of 
sensory nerve endings in articular cartilage means that, 
when loaded, there is no experience of pain. However, it is 
thought by some that nutrition of the deep articular carti-
lage comes from the subchondral bone, rather than the 
synovial fluid, which nourishes the superficial layers.
Function of subchondral bone and the osteochondral junction
Subchondral bone acts as the mechanical support of the 
joint linking to the diaphyseal bone. The length of the dia-
physeal bone allows an increase in the lever arm of appro-
priate muscles to improve the power of the joint’s action. 
The bone contains cells, haemopoietic tissue, and a nerve 
and blood supply.
The osteochondral junction has three functions:
1) It is the transitional zone between the soft articular 
cartilage and the hard subchondral bone and there-
fore has mechanical properties that are important;1
2) The vertical portions of the arcades of collagen type 
II pass through it, anchoring the articular cartilage 
to the subchondral bone (Fig. 1);
3) Cytokines pass across it at a molecular level, creat-
ing ‘cross-talk’ between the chondrocytes and 
bone cells.
Changes at the osteochondral junction 
associated with OA
There is a direct correlation between the loss of articular 
cartilage and the expansion of the subchondral bone. 
Structural, biochemical and biomechanical changes occur 
at the osteochondral junction in association with OA. 
These changes can be viewed in two ways:5
 • compromise of the barrier between the synovium and 
the subchondral bone; and
 • osteochondral plasticity with responses from the adja-
cent structures, i.e. the synovial membrane, cartilage 
and bone, forming new tissue with different morpho-
logical and functional characteristics.
Bone marrow lesions and subchondral 
bone remodelling
The earliest signs of OA in the subchondral bone are bone 
marrow lesions (BML; excessive water signals in bone on 
MRI) seen on MRI scanning.13 They are thought to result 
Non-calcified cartilage
Calcified cartilage
Subchondral bone
Tidemark
Vascular channelCollagen fibre
Fig. 1. Diagram showing the structure of the osteochondral junction
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from remodelling of the subchondral bone due to 
mechanical overload. If the abnormal loading continues, 
then the BMLs persist; there is an associated loss of articu-
lar cartilage and symptomatic OA develops (Fig. 2). In the 
subchondral tissue, the amount of bone increases but the 
mineral density is reduced. This is seen radiographically as 
osteosclerosis where there are fewer, but thicker trabeculae14 
(Fig. 3). The loss of mineralisation and increased bone vol-
ume lowers the tissue stiffness (Young’s modulus) but 
increases the structural stiffness.
Histology of bone marrow lesions
In a systematic review of the histology of bone marrow 
lesions, Loef et al3 found 13 studies of OA, of which eight 
Bone marrow lesion on MRI
Progressive cartilage loss &
Development of OA
Positively correlates with
synovitis severity
BML >70% denuded joint surface
Subchondral cysts 
Subchondral bone attrition
↑ BML size
Subchondral microfractures
Abnormal mechanical loading 
OA
Progression
Fig. 2. Proposed scheme for the development of bone marrow lesions and progression of osteoarthritis (based on data from Hügel 
and Guerts13)
1 cm
1 cm
Fig. 3. Matched Magnetic Resonance (MR) and histology images at (top row) medial and (bottom row) lateral tibial plateau. note 
the area of homogeneous low signal on MR (white arrowheads) corresponds to an area of trabecular thickening on histology (black 
arrowheads). (reproduced from Mackay et al,14 with permission from Elsevier)
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used pre-operative MRI scans and three correlated these 
with tissue samples. Three investigated bone remodelling 
using micro-computed tomography.
Signs of bone remodelling were demonstrated by an 
increase in bone density, thickening of the subchondral 
plate and an increase in trabecular number, volume and 
thickness when compared with non-BML samples. A 
‘structural model index’ that reflected the trabecular 
shape was found to be increased in BML samples in one 
article but decreased in two others.
The histological findings were:
1) Cell death
a) Bone necrosis (empty lacunae suggesting lack 
of osteocytes) (one study)
b) Swollen or disintegrated adipose tissue cells 
(three studies), fat necrosis affecting 5% to 60% 
of marrow fat (one study) and necrosis signifi-
cantly greater in BMLs than in areas without 
BMLs (one study)
2) Fibrosis
a) Adipose tissue partially replaced with fibrous 
and fibrovascular tissue (ten studies)
b) Fibrosis found in 85% of patients amounting to 
20% of the tissue volume (one study)
3) Cellular infiltration
a) Increased cellular infiltration was shown in the 
BML group compared to the non-BML group 
(one study)
b) no study described the cellular infiltration
4) Vascularity
a) Increased bone vascularity in BMLs compared 
to controls (three studies) being four times that 
of controls in BMLs
They concluded that more studies of better quality are 
needed.
Subchondral bone circulation in OA
Subchondral bone perfusion kinetics in human OA has 
been investigated by using dynamic contrast-enhanced 
(DCE) MRI. Aaron et al15 compared 15 patients with severe 
OA of the knee with eight normal controls. They investi-
gated the lateral tibial plateau to avoid the multiple bone 
changes seen in the affected medial compartment. They 
found that OA bone has venous outflow stasis and a 
decrease in arterial inflow when compared to normal 
bone. They commented that this venous outlet syndrome 
has known effects on intraosseous hypertension, reduc-
tions in perfusion and hypoxia. Since osteoblasts are 
affected by hypoxia changes in their cytokine profiles in 
OA suggest that there might be a relationship between 
tissue perfusion and osteoblast function.
Cellular and biomolecular response  
of osteochondral tissues
The principal cells involved in subchondral bone remodel-
ling are osteoblasts, osteoclasts and macrophages (Fig. 4). 
In humans with OA, microfractures and neovascularisa-
tion are seen in the subchondral bone and at the osteo-
chondral junction. This triggers a reparative response with 
new blood vessel formation and inflammation with the 
typical radiological findings in subchondral bone of osteo-
phyte formation, cysts and subchondral sclerosis (Fig. 5).1 
The effect of age on the osteochondral tissue in humans is 
poorly understood; as bone demineralisation occurs there 
is a corresponding increase in organic content. In OA, the 
organic content does not increase with demineralisation 
implying that there is an increase in osteoid tissue. Hypo-
mineralisation is associated with an altered alpha-1 to 
alpha-2 chain ratio in the composition of collagen type I in 
the subchondral zone of osteoarthritic samples.16 The nor-
mal homeostasis between osteoblasts and osteoclasts is 
disrupted and osteoclast activity increases. In normal 
bone, fractures heal back to bone, but in OA the micro-
fractures heal with fibrous vascular tissue and under- 
mineralised sclerotic bone, implying a similar process to 
delayed fracture healing.17
Both osteoblast and osteoclast activity increase in OA 
by 96% and 190%, respectively, but since bone loss over-
all is not observed, this indicates that the osteoblast- 
mediated bone formation has a distinct role in OA.1 Bone 
remodelling involves the interplay between the osteo-
blasts, osteoclasts and bone marrow mesenchymal stem 
cells (MSCs). Rather than mature osteoblasts lining the 
resorption pits in damaged subchondral bone, the osteo-
blasts come from bone marrow-derived MSCs migrating 
and transforming into osteoblasts.18 MSCs derived from 
bone marrow lesions in OA have lower mineralisation 
capacity and slower proliferation. It is thought that this 
may be an effect of the inflammatory process.19
Osteoblasts from the subchondral bone can induce 
chondrocytes to increase MMP-13 expression and 
decrease aggrecan production, a pro-catabolic state. OA 
chondrocytes can affect osteoblast function by causing 
the latter to increase MMP-1 expression; although these 
data are from end-stage, rather than early-stage OA.1 OA 
osteoblasts also express high levels of inflammatory 
cytokines such as transforming growth factor β1 (TGFβ1) 
and prostaglandin E2 (PGE2). Overexpression of inflam-
matory cytokines is thought to contribute to subchondral 
bone disturbance. Figure 6 shows a proposed biomolecu-
lar interaction at the osteochondral junction.
In addition, the bone marrow osteocytes send apoptotic 
signals in response to microfractures; these increase osteo-
clastogenesis20 and also decreased sclerostin  production.21 
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Sclerostin inhibits osteoblasts. When the subchondral osteo-
clasts become activated, they form cutting cones that breech 
the subchondral plate and enter the non-calcified cartilage 
layer (Fig. 7). This may be associated with fissuring of the 
articular cartilage down to the tidemark and into the sub-
chondral plate. Separation between the chondral layer and 
Osteoclast Osteoblast Macrophage
Sensory nerve and
blood vessel
Fig. 4. Diagram showing the cells involved in bone remodelling. note the perforation of the osteochondral junction by an osteoclast 
taking blood vessel and sensory nerve supply into the deep layer of articular cartilage
Abnormal mechanical loading 
Recruitment of immune cells 
(including mono- and multi-nucleated cells)
Subchondral microfractures
Unresolved bone marrow oedema
Bone cyst formation
Osteosclerosis
Withdrawal of multi-nucleated cells,
infiltration of T-cells remodelling
Fig. 5. Proposed scheme for the development of osteoarthritis in a post-traumatic model (based on data from Weber et al1)
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the subchondral plate is seen macroscopically as a chondral 
defect. Breeching of the subchondral plate coupled with the 
chondral damage allows the movement of fluid, cells and 
molecules between the bone and the joint cavity. Mechani-
cal forces can also affect and worsen the destruction.
The tissues may respond by duplicating the tidemark 
within the non-calcified layer with a ‘second front’ of 
perivascular ossification and subchondral thickening. 
new blood vessel formation may occur with ingrowth 
into the cartilage accompanied by sensory nerves. The for-
mation of osteophytes, an attempt to decrease the load 
across the joint by increasing its surface area, depends on 
neovascularisation. normal chondrocytes are resistant to 
vascular invasion secreting anti-angiogenic factors, such 
↑Sox9
↑TGF-α
↑WISP-1
OPG/
RANK/
RANKL
↑VEGF
↑PDGF
↑NGF
↑HGF
↓aggrecans
↑MMP3
↑sclerostin
↑VEGF
Chondrocyte
cluster
↓sclerostin
Osteoclast Osteoblast Macrophage
Fig. 6. Diagram of the biomolecular interactions in osteoarthritis (original drawing, adapted from Suri and Walsh5)
Cytokines (TNF, IL-1)
Osteophyte
Osteoclastogenesis
Cyst/Erosion
Uncoupled bone remodelling
Cartilage damage
Pannus
Fibrin
Synovitis
Cytokines/growth factors
Fig. 7. Diagram of the interaction of synovial inflammation and mechanical subchondral damage in osteoarthritis (original drawing, 
adapted from Hügel and Guerts13)
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as the regulatory peptides troponin I and thrombospon-
din-1,22,23 and inhibitors of matrix degrading enzymes, 
including tissue inhibitors of metalloproteinases (TIMPs), 
secretory leukocyte proteinase inhibitor and plasminogen 
activator inhibitor-1.24 The fissures in the articular cartilage 
may be filled with fibrocartilage as an attempt at repair, 
with invasion of fibroblasts via the new blood vessels.
Immune cells in OA
Immune cells are known to be active in fracture healing. It 
is postulated that the persistent bone marrow lesions have 
similarities with the pathogenesis of delayed fracture heal-
ing.1 Macrophages, as well as T and B cells participate 
actively in the healing process by migrating into the frac-
ture site to serve various functions.25 T and B cells are 
involved in osteoclastogenesis and bone catabolism. The 
osteoprotegerin/receptor activator of the nuclear factor 
kappa-B ligand (OPG/RAnKL) system allows cross-talk 
between immune cells and bone cells. RAnKL is secreted 
by osteocytes and can bind to RAnK on the surface of 
osteoclast precursors. This initiates osteoclastogenesis 
and bone resorption during the remodelling process.26 
However, immune cells such as B lymphocytes could be 
another source of RAnKL for osteoclastogenesis.27
In late-stage OA, the number of CD68+ macrophages 
and CD20+ B lymphocytes are significantly higher in the 
sclerotic region of subchondral bone than in non-sclerotic 
areas.28 B cells and their secretion of IL-10 are associated 
with delayed bone fracture healing.29 Therefore, B cells 
are also suspected to have a hand in the defective repair of 
subchondral bone in OA. However, more work is needed 
to support the notion that persistent BMLs have the same 
pathogenesis as delayed fracture healing.
TGF-β1 is activated in the subchondral bone in response 
to altered mechanical loading.11 TGF-β1 concentration 
also increases in the subchondral bone of human osteo-
arthritis. High concentrations of TGF-β1 induce formation 
of nestin + MSC clusters, leading to aberrant bone forma-
tion accompanied by increased angiogenesis. Transgenic 
expression of active TGF-β1 in osteoblastic cells induces 
OA. Inhibition of TGF-β activity in subchondral bone 
attenuates degeneration of OA articular cartilage.
Effects of inflammation on bone remodelling in OA
Inflammation is a phase of bone fracture healing, with 
inflammatory cells regulating the process by secreting 
inflammatory cytokines and chemotactic mediators,30 as 
well as growth factors, to recruit and stimulate both 
immune cells and progenitor cells for remodelling of the 
fracture site. Monocytes and macrophages are capable of 
releasing cytokines such as BMP-2, BMP-4 and TGF-β1, 
which can stimulate osteoblast differentiation and prolif-
eration.31 Weber et al1 propose that changes in TGFβ1 
level after subchondral bone micro-fractures might lead to 
activation of the adaptive immune system. Imbalance in 
inflammatory and anti-inflammatory cells might contrib-
ute to delayed union or nonunion of micro-fractures, con-
tributing to subchondral bone sclerosis formation and the 
persistence of the disorder. Identifying a unique pattern of 
adaptive immune system activation in OA would throw 
light on the development of new diagnostic and thera-
peutic strategies for OA.
Although synovial inflammation secondary to cartilage 
wear-debris is well-known, OA may be a systemically 
induced inflammatory disease. In the peripheral blood of 
OA patients, a significant aberrant ratio of CD4+/CD8+ 
cells has been found.32,33 The highly vascularised synovium 
may be a gateway for systemic inflammatory cytokines to 
affect the joint (Fig. 6).13 Synovial membrane is a source of 
inflammatory cytokines such as IL-1, IL-6 and TnF,34 which 
can be released by mast cells, which are present in great 
abundance in OA synovium.35 Mast cells can also recruit 
innate immune cells.36 Mast cells can therefore contribute 
to inflammation as well as subchondral bone pathology. It 
is important to emphasise that there is no direct evidence 
that inflammation causes osteosclerosis in subchondral 
bone, but the presence of high numbers of macrophages 
and B lymphocytes suggests there might be.28
Conclusions
Subchondral bone remodelling is an integral part of the 
pathology of OA. However, the response of subchondral 
bone is not independent of the rest of the joint. Alterations 
from normal in the articular cartilage results in changes in 
subchondral bone and vice versa. The usual initiator of 
subchondral remodelling is abnormal mechanical loads. 
These lead to microfractures and what may be a fracture 
healing response. This response involves macrophages, 
MSCs forming osteoblasts and osteoclastogenesis through 
chemical signals. The effect is to increase bone tissue cou-
pled with demineralisation which results in fewer, but 
thicker, trabeculae. This is seen as osteosclerosis on imag-
ing. Increased vascularisation can be seen on MRI early in 
the evolution of OA. Osteoclasts penetrate the osteochon-
dral junction allowing new blood vessels and sensory 
nerves to infiltrate the deep layer of the articular cartilage. 
Coupled with articular cartilage fissuring and loss, the 
synovial fluid and its associated cytokines can directly 
infiltrate the subchondral bone and affect all the cells pre-
sent. The progression of OA occurs when the abnormal 
mechanical environment continues to the point where 
recovery of the tissue is not possible. It is thought that this 
is when subchondral sclerosis has occurred. Drug thera-
pies to alter the chemical pathways are not expected to 
work from this point and, apart from pain relief, surgical 
therapies such as osteotomy are more likely to be limited 
to reducing the progression of the disorder.
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